Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 and Nanoliposomal Irinotecan in Advanced GI Cancers
NCT03368963Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- Jan 2018
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil, irinotecan liposome injection in gastrointestinal cancer, colorectal cancer (CRC), pancreatic cancer (PC), gastric cancer (GC), cholangiocarcinoma (CCA), sponsored by Emory University. Started Jan 2018; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilirinotecan liposome injection
03
Conditions
gastrointestinal cancercolorectal cancer (CRC)pancreatic cancer (PC)gastric cancer (GC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03368963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03368963.